Evidence map›Paper›PMID 35890282›Full record

ArticlePharmaceutics2022

Design and Functional Characterization of HIV-1 Envelope Protein-Coupled T Helper Liposomes.

Dominik Damm, Ehsan Suleiman, Hannah Theobald, Jannik T Wagner, Mirjam Batzoni, Bianca Ahlfeld Née Kohlhauser, Bernd Walkenfort, Jens-Christian Albrecht, Jidnyasa Ingale, Lifei Yang and 5 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Modulation of immune responses to liposomal vaccines by intrastructural help.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2023
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Dominik DammInstitute of Clinical and Molecular Virology, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany.ORCID 0000-0001-7260-6368
Ehsan SuleimanDepartment of Biotechnology, University of Natural Resources and Life Sciences, 1190 Vienna, Austria.
Hannah TheobaldInstitute of Clinical and Molecular Virology, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany.
Jannik T WagnerInstitute of Clinical and Molecular Virology, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany.ORCID 0000-0002-5882-848X
Mirjam BatzoniDepartment of Biotechnology, University of Natural Resources and Life Sciences, 1190 Vienna, Austria.
Bianca Ahlfeld Née KohlhauserDepartment of Biotechnology, University of Natural Resources and Life Sciences, 1190 Vienna, Austria.
Bernd WalkenfortElectron Microscopy Unit (EMU), Imaging Center Essen (IMCES), Faculty of Medicine, University of Duisburg-Essen, 45147 Essen, Germany.ORCID 0000-0002-7789-3340
Jens-Christian AlbrechtInstitute of Clinical and Molecular Virology, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany.
Jidnyasa IngaleVaccine Business Unit, Takeda Pharmaceuticals, Cambridge, MA 02139, USA.
Lifei YangDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Mike HasenbergElectron Microscopy Unit (EMU), Imaging Center Essen (IMCES), Faculty of Medicine, University of Duisburg-Essen, 45147 Essen, Germany.ORCID 0000-0001-7466-1846
Richard T WyattDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-7085-1351
Karola Vorauer-UhlDepartment of Biotechnology, University of Natural Resources and Life Sciences, 1190 Vienna, Austria.ORCID 0000-0003-4217-8846
Klaus ÜberlaInstitute of Clinical and Molecular Virology, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany.ORCID 0000-0001-7822-3835
Vladimir TemchuraInstitute of Clinical and Molecular Virology, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany.ORCID 0000-0002-8600-252X
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEBOKU University · ATScripps Research Institute · USUniversity of Duisburg-Essen · DETakeda (United States) · US

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
Project 2_NillaP01AI157299 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI WYATT, RICHARD THOMAS · 2021 to 2025
$17.3M
Non-Human PrimatesP01AI104722 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI KARLSSON HEDESTAM, GUNILLA · 2014 to 2018
$14.6M
European Union's Horizon 2020 research and innovation programme 681137NIAID NIH HHS P01 AI104722NIAID NIH HHS P01 AI157299NIAID NIH HHS UM1 AI144462
6 · The paper itself

Abstract

Functionalization of experimental HIV-1 virus-like particle vaccines with heterologous T helper epitopes (T helper VLPs) can modulate the humoral immune response via intrastructural help (ISH). Current advances in the conjugation of native-like HIV-1 envelope trimers (Env) onto liposomes and encapsulation of peptide epitopes into these nanoparticles renders this GMP-scalable liposomal platform a feasible alternative to VLP-based vaccines. In this study, we designed and analyzed customizable Env-conjugated T helper liposomes. First, we passively encapsulated T helper peptides into a well-characterized liposome formulation displaying a dense array of Env trimers on the surface. We confirmed the closed pre-fusion state of the coupled Env trimers by immunogold staining with conformation-specific antibodies. These peptide-loaded Env-liposome conjugates efficiently activated Env-specific B cells, which further induced proliferation of CD4+ T cells by presentation of liposome-derived peptides on MHC-II molecules. The peptide encapsulation process was then quantitatively improved by an electrostatically driven approach using an overall anionic lipid formulation. We demonstrated that peptides delivered by liposomes were presented by DCs in secondary lymphoid organs after intramuscular immunization of mice. UFO (uncleaved prefusion optimized) Env trimers were covalently coupled to peptide-loaded anionic liposomes by His-tag/NTA(Ni) interactions and EDC/Sulfo-NHS crosslinking. EM imaging revealed a moderately dense array of well-folded Env trimers on the liposomal surface. The conformation was verified by liposomal surface FACS. Furthermore, anionic Env-coupled T helper liposomes effectively induced Env-specific B cell activation and proliferation in a comparable range to T helper VLPs. Taken together, we demonstrated that T helper VLPs can be substituted with customizable and GMP-scalable liposomal nanoparticles as a perspective for future preclinical and clinical HIV vaccine applications. The functional nanoparticle characterization assays shown in this study can be applied to other systems of synthetic nanoparticles delivering antigens derived from various pathogens.

Indexed as

coupling mechanismEnv trimerfunctionalizationGMPHIVimmunogold stainingintrastructural helppeptide encapsulationT helper liposomesvaccine

Identifiers

PMID35890282
PMCPMC9318220
OpenAlexW4283759226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.